- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02442128
Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children
Using Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children: a Randomized Prospective Study
Several methods have been proposed to improve intubating conditions and minimize sevoflurane induction time during sevoflurane induction in children. These include clonidine premedication, [5] addition of nitrous oxide, [6] opioids, [7,8] or propofol [9].
Four Studies evaluated sevoflurane alone for intubation (9-12).Aim of this study: is to evaluate the effects of two different dose of propofol preceded by a fixed dose of fentanyl during sevoflurane induction on quality of tracheal intubation in children undergoing elective surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients fasted 6 h for solid food, but clear fluids will be given for up to 4 h pre- operatively. All patients will be pre-medicated with 0.3 mg/kg oral midazolam (maximum dose of 12 mg) 30 min before induction and EMLA cream will be applied to the dorsum of both hands 1 h prior to surgery. Children who refuse to take oral premedication will be excluded. One parent will be allowed to accompany the child into the pre-operative holding area. On arrival in the anesthetic room, baseline heart rate, pulse oximeter oxygen saturation and non-invasive blood pressure will be measured. A side-stream connector for the measurement of end-tidal sevoflurane concentration and end-tidal carbon dioxide will be introduced between the face mask and a Mapelson D breathing system.
- Anesthesia will be induced by a circle system using a vaporizer concentration of 6% sevoflurane in an oxygen flow of 6 L/min. After loss of consciousness and the eyelash reflex, sevoflurane concentration will be reduced to 3 % and intravenous access will be secured in all children using a 22-G cannula sited on the dorsum of a hand and the facemask ventilation will be then assisted using a 10 cm H2O inspiratory pressure at a ventilatory frequency of 16min. Once IV cannula is administered the inspired concentration of sevoflurane was decreased to 1% in oxygen.
- The investigating anesthetist will open a sealed envelope allocating the patient to one of two groups: Group 1 = fentanyl 2 μg/kg and propofol 2 mg/kg or Group 2 = fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. In both groups, fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
- Ninety seconds after administration of propofol, laryngoscopy and tracheal intubation with an appropriate sized non cuffed tube will be performed using a suitable sized Macintosh laryngoscope by a second an experienced unbiased anesthetist who enters the room and, unaware of the patient's randomization group. Intubating conditions will be evaluated as proposed by Viby-Mogensen and colleagues [9]. Five factors will be considered for assessment, jaw relaxation; ease of laryngoscopy; vocal cord position; coughing; and patient movement as excellent (1), good (2) or poor (3).
- Overall intubating conditions will be recorded as 'excellent' if all score 1, 'good' if any scored 2, and 'poor' if there will be any scores of 3. Intubation will not be attempted if the vocal cords is closed to avoid airway complications and any failure to intubate the trachea or prolonged coughing on intubation will be managed using suxamethonium or a non-depolarising muscle relaxant where clinically indicated.
- Following successful tracheal intubation, the study will be ended at this point, ventilation will be gently assisted and anesthesia will be maintained at the discretion of the anesthesiologist. In both groups HR, MAP and SPO2 will be measured immediately before the inhaled induction, after propofol administration, prior to intubation, immediately after intubation and at 2 and 5min min after intubation. Occurrence of bradycardia, hypotension or other significant complication will be recorded.
- The first investigating anesthetist is unblinded and responsible for preparing and administering all drugs. The second anesthetist will be blinded to drug allocation, intubate patients, record all parameters, and grade the airway conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Riyadh, Saudi Arabia, 11411
- King Saud University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA physical status I and II patients, Undergoing elective ENT surgery
Exclusion Criteria:
• History or examination suggested a potentially difficult intubation,
- Significant respiratory disease or poorly controlled asthma,
- gastrooesophageal reflux,
- neurological or neuromuscular disease,
- any condition that would preclude the use of this technique,
- known sensitivity to the drugs used,
- history or examination suggestive of cardiac illness,
- history of respiratory tract infection in the previous 2 weeks,
- history of malignant hyperthermia or other myopathy,
- who refused to undergo an inhalational induction,
- Children in whom i.v. access had already been established.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group1
comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
|
fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Other Names:
fentanyl 2 μg/kg and propofol 3 mg/kg.
Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Other Names:
|
Active Comparator: Group 2
comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg.
Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
|
fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Other Names:
fentanyl 2 μg/kg and propofol 3 mg/kg.
Both test drugs will be made up to 10 ml with saline.
fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of excellent intubating conditions
Time Frame: during start of endotracheal intubation (10 seconds)
|
Intubating conditions will be evaluated as proposed by Viby-Mogensen and colleagues . Five factors will be considered for assessment, jaw relaxation; ease of laryngoscopy; vocal cord position; coughing; and patient movement as excellent (1), good (2) or poor (3). Overall intubating conditions will be recorded as 'excellent' if all score 1, 'good' if any scored 2, and 'poor' if there will be any scores of 3. Intubation will not be attempted if the vocal cords is closed to avoid airway complications and any failure to intubate the trachea or prolonged coughing on intubation will be managed using suxamethonium or a non-depolarising muscle relaxant where clinically indicated. |
during start of endotracheal intubation (10 seconds)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The hemodynamic response
Time Frame: 15 minutes
|
. In both groups HR, MAP and SPO2 will be measured immediately before the inhaled induction, after propofol administration, prior to intubation, immediately after intubation and at 2 and 5min min after intubation.
Occurrence of bradycardia, hypotension or other significant complication will be recorded.
|
15 minutes
|
The duration of intubation
Time Frame: during endotracheal intubation (30 seconds)
|
time between the initial introduction of the laryngoscope and the final placement of the tracheal tube
|
during endotracheal intubation (30 seconds)
|
number of intubation attempts
Time Frame: 5 minutes
|
number of intubation attempts before successful intubation
|
5 minutes
|
occurrence of complication
Time Frame: 1 day
|
bradycardia, hypotension , laryngeal spasm, desaturation, stridor or other significant complication will be recorded.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ashraf A Abdelhalim, MD, King Saud University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neuromuscular Manifestations
- Muscle Hypotonia
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Fentanyl
- Propofol
Other Study ID Numbers
- E-14-1071
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anesthesia Intubation Complication
-
Instituto de Investigación Sanitaria de la Fundación...UnknownAirway Complication of Anesthesia | Anesthesia Intubation ComplicationSpain
-
University of MinnesotaRecruitingAnesthesia | Anesthesia Intubation ComplicationUnited States
-
Hospital General Universitario de ValenciaFIPSERecruitingDifficult Intubation | Anesthesia Intubation ComplicationSpain
-
Udayana UniversityCompletedAnesthesia | Intubation Complication | Intubation;DifficultIndonesia
-
Emory UniversityTerminatedAirway Morbidity | Intubation Complication | Anesthesia Intubation Complication | Tracheal Intubation Morbidity | Failed or Difficult Intubation, SequelaUnited States
-
University of Alabama at BirminghamRecruiting
-
Zagazig UniversityCompletedAnesthesia Intubation ComplicationEgypt
-
Ankara City Hospital BilkentCompletedAnesthesia Intubation ComplicationTurkey
-
Senthil G. KrishnaCompletedAnesthesia Intubation ComplicationUnited States
-
Antalya Training and Research HospitalCompletedAnesthesia Intubation ComplicationTurkey
Clinical Trials on propofol /Fentanyl
-
University of Wisconsin, MadisonCompletedLymphoma | LeukemiaUnited States
-
Ain Shams UniversityRecruitingSevoflurane | Dexmedetomidine | Spine Surgery | Propofol | Fentanyl | Motor Evoked Potential | Somatosensory Evoked PotentialEgypt
-
The Affiliated Hospital of Qingdao UniversityNot yet recruitingRespiratory Insufficiency
-
Charles University, Czech RepublicMilitary University Hospital, PragueRecruitingVentilatory Depression | Sedation ComplicationCzechia
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPancreatic CancerUnited States
-
Heidelberg UniversityCompletedAnesthesia | Immunotoxicity | Inert Gas NarcosisGermany
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedFailed Moderate Sedation During Procedure
-
Medical University of SilesiaCompleted
-
Jiangsu Hengrui Pharmaceutical Co., Ltd.Unknown